Anthracyclines for acute lymphoblastic leukemia in a child with congenital long QT syndrome

Int J Hematol. 2011 Jun;93(6):802-805. doi: 10.1007/s12185-011-0851-6. Epub 2011 Apr 22.

Abstract

Anthracyclines are key drugs for the treatment of children with acute lymphoblastic leukemia (ALL). However, anthracyclines are known to induce QT prolongation, and life-threatening complications, such as torsades de pointe may also occur. To date, there have been no reports on the use of anthracyclines in patients with congenital long QT syndrome (LQTS). We report a child with ALL complicated by congenital LQTS who was treated with anthracyclines. The administration of anthracyclines caused QT-interval prolongation, but this was uneventful with the concomitant administration of magnesium sulfate.

Publication types

  • Case Reports

MeSH terms

  • Anthracyclines / administration & dosage
  • Anthracyclines / therapeutic use*
  • Anti-Arrhythmia Agents / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Electrocardiography
  • Female
  • Humans
  • Long QT Syndrome / complications*
  • Long QT Syndrome / congenital
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Remission Induction
  • Treatment Outcome

Substances

  • Anthracyclines
  • Anti-Arrhythmia Agents
  • Antineoplastic Agents